Drugmaker Sanofi to raise over $11 billion via sale of Regeneron shares


© Reuters. FILE PHOTO: Sanofi logo is seen in Paris

PARIS (Reuters) – Sanofi (PA:) will raise over $11 billion (8.93 billion pounds) from the sale of 21.6 million shares in its U.S. partner Regeneron (O:), the French drugmaker said on Wednesday, adding it would use the proceeds for innovation and general growth.

Earlier this week, Regeneron had said it would repurchase about $5 billion of its shares directly from Sanofi, without altering their over-a-decade-long partnership.

Sanofi is selling the Regeneron shares at $515.00 per share – a discount of around 5.5% to Regeneron’s closing price of $545.21 on May 26, and raising gross proceeds of $11.1 billion.

Sanofi will continue to own approximately 400,000 shares of Regeneron’s common stock.

Sanofi could end up raising $11.7 billion, if the underwriters on the deal exercise their option to buy up a further 1.2 million Regeneron shares.

The collaboration between Sanofi and Regeneron dates back to 2003 and has resulted in five approved treatments to date – including eczema drug Dupixent – with additional candidates in clinical development.

Investment banks Bank of America (NYSE:) Securities, Goldman Sachs (NYSE:), Barclays (LON:), BNP Paribas (PA:), Citigroup (NYSE:), JP Morgan and Morgan Stanley (NYSE:) worked on Sanofi’s Regeneron stake sale.

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.





READ SOURCE